CreditReports.dk
HomeScreen companies

Ascendis Pharma Oncology Division A/S Financials, key figures and credit report

CVR number: 41034076 Established 2019 Industry: 21 Manufacture of basic pharmaceutical products and pharmaceutical preparations
Company contact details
Tuborg Boulevard 12, 2900 Hellerup
Gross profit -85 226.0 kEUR FY 2025 +7.8% vs 2024
EBIT -85 274.0 kEUR FY 2025 +7.9% vs 2024
Net debt 501 629.0 kEUR FY 2025 +28.1% vs 2024
Quick ratio 7.1 FY 2025

Company information

Official name
Ascendis Pharma Oncology Division A/S
Established
2019
Company form
Limited company
Industry

Data sources and methodology

The information about Ascendis Pharma Oncology Division A/S combines official Danish company and financial-statement data with indicators calculated by Valuatum Oy.

Company information

Name, CVR number, address, industry and legal form are based on the Danish Central Business Register (CVR).

CVR / Virk

Annual accounts

Financial figures come from annual reports published through the Danish Business Authority. The latest financial year used is 2025.

Open the 2025 annual report

Key figures and credit risk

Valuatum Oy calculates financial ratios, comparisons and credit-risk indicators from the available accounts. The results support analysis and do not constitute a standalone credit decision.

Valuatum Oy

About Ascendis Pharma Oncology Division A/S

Ascendis Pharma Oncology Division A/S (CVR number: 4103407-6) is a company from GENTOFTE. The company recorded a gross profit of -85226 kEUR in 2025. The operating profit was -85.3 mEUR, while net earnings were -110.1 mEUR. The profitability of the company measured by Return on Assets (ROA) was -19.1 %, which can be considered poor and Return on Equity (ROE) was -222486.9 %, which can be considered poor. The equity ratio, a key indicator for solidity, stood at -100 %. This indicates that the company's debt surpasses the value of its total assets, posing significant financial risk. Ascendis Pharma Oncology Division A/S's liquidity measured by quick ratio was 0 which is at a very low level. Thus, the company is in an unstable financial position, with its liquid assets significantly undermatching its current liabilities. This severe liquidity deficiency may lead to financial distress and threaten the company's operational continuity.

Financial information

See financials

Gross profit (kEUR)

EBIT (kEUR)

Profitability

Solidity

Key figures (kEUR)

See financials
2021
2022
2023
2024
2025
Volume
Net sales
Gross profit-46 676.71-62 367.39- 140 146.00-92 475.00-85 226.00
EBIT-46 763.20-62 458.51- 140 193.00-92 552.00-85 274.00
Net earnings-47 980.23-64 912.25- 144 110.00- 106 375.00- 110 131.00
Shareholders equity total-76 108.65- 141 020.90- 285 131.00- 391 506.00- 501 637.00
Balance sheet total (assets)5 608.145 604.08457.0099.00
Net debt81 259.78146 130.56285 134.00391 492.00501 629.00
Profitability
EBIT-%
ROA-79.0 %-54.7 %-64.6 %-27.1 %-19.1 %
ROE- 681.7 %-1 157.9 %-4 755.3 %-38 264.4 %- 222 486.9 %
ROI-80.8 %-54.7 %-64.6 %-27.1 %-19.1 %
Economic value added (EVA)-46 953.53-62 662.98- 140 251.38-92 236.28-77 609.43
Solvency
Equity ratio-93.1 %-96.2 %-99.8 %- 100.0 %- 100.0 %
Gearing- 107.4 %- 104.0 %- 100.2 %- 100.0 %- 100.0 %
Relative net indebtedness %
Liquidity
Quick ratio404.5352.438.17.1
Current ratio404.5352.438.17.1
Cash and cash equivalents449.65478.52442.0099.00
Capital use efficiency
Trade debtors turnover (days)
Net working capital %

Variable visualization

ROA FY 2025
-19.1%
Rating 1/100
-20%
0%
4%
11%
24%
60%
Graph showing the distribution of the variable
Equity ratio FY 2025
-100.0%
Rating 0/100
-1%
21%
50%
81%
99%
100%
Graph showing the distribution of the variable

Credit Risk Report

Affordable credit risk report
for basic company risk checks.

Check the creditworthiness of Ascendis Pharma Oncology Division A/S before offering payment terms. The report combines financial figures, risk scores, credit rating, bankruptcy risk and a credit-limit recommendation in one PDF.

AI Credit Risk Report

The core credit-risk figures,
explained with AI.

The AI Credit Risk Report contains the same core financial figures and risk measures as the Credit Risk Report. It also provides written analysis of the company's finances, risks, repayment capacity and assets, together with relevant context from web searches.

  1. 01 Includes the same financial figures, risk scores, credit rating and bankruptcy risk as the Credit Risk Report.
  2. 02 AI complements the analysis with web searches and brings in the relevant company and operating-environment observations.
  3. 03 The written analysis is more precise, more readable and better suited to decision-making.
€3 / report

Company-specific, AI-assisted credit risk report in PDF format.

For larger customers

Reports can be tailored to your own credit process: content structure, peer groups, risk thresholds, delivery method and AI-analysis weightings can all be adapted to your needs.
Ask about a tailored solution: contact@creditreports.dk

The report is intended for an initial financial assessment. · The final credit decision and any further verification are always the user's responsibility. · One-time payment, no subscription.

What the report includes

8 sections
Financial figures
Risk scores
Credit rating
Bankruptcy risk
AI web-search highlights
Written risk analysis
Conclusions
Ratio appendices

Roles

Companies in the same industry

Page generated